Genital Diseases, Female  >>  temozolomide  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
temozolomide / Generic mfg.
NCT01113957 / 2009-015082-31: A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Completed
2
168
US, Canada, Europe, RoW
ABT-888, ABT-888, veliparib, pegylated liposomal doxorubicin, doxil/caelyx, temozolomide, temozolomide, temodar/temodal
AbbVie (prior sponsor, Abbott)
Ovarian Cancer
06/13
06/13
NCT01618136 / 2011-001959-37: An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Completed
1/2
41
Europe
E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
Eisai Limited
Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma, B-cell Malignancy, Low-grade
07/15
07/15

Download Options